Theorem Clinical Research

Drug Sponsors

Neomed creates a new Biologics and Vaccine Center of Excellence

Thursday, February 5, 2015 12:15 PM

Neomed has launched the Biologics and Vaccine Center of Excellence in Laval under a proposed partnership with GlaxoSmithKline (GSK). This Center will be unique in Canada and GSK has committed $47 million towards its establishment. Neomed is a nonprofit that fosters the development of promising therapeutic approaches emerging from academia and biotechnology companies and is jointly funded by the pharmaceutical industry, the Ministère de l'Économie, de l'Innovation et des Exportations du Québec and the Networks of Centers of Excellence (NCE) of Canada.

More... »

Quest Diagnostics

The Medicines Company acquires Annovation Biopharma

Thursday, February 5, 2015 12:08 PM

The Medicines Company has completed its acquisition of all of the outstanding equity of Annovation Biopharma, a company focused on creating more effective, safer therapies for anesthesia and critical care. Based on technology licensed from Massachusetts General Hospital, Annovation is developing ABP-700, a novel intravenous anesthetic which in phase I clinical studies has demonstrated potent and rapidly reversible anesthetic effects.

More... »

Pfizer to acquire Hospira for $17 billion

Thursday, February 5, 2015 12:06 PM

Pfizer has agreed to acquire Hospira, a provider of injectable drugs and infusion technologies and a global provider in biosimilars headquartered in Lake Forest, Ill., for $90 a share in cash, for a total enterprise value of approximately $17 billion.

More... »

Water Street invests in generic injectable drug services company Custopharm

Wednesday, February 4, 2015 01:32 PM

Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry headquartered in Chicago, has invested in Custopharm, a generic injectable drug services company. Water Street's team has committed equity to both acquire and expand the Carlsbad, Calif.-based company. The healthcare firm has recruited William Larkins, Ph.D., former vice president and general manager of Bedford Laboratories, as CEO of Custopharm.

More... »

Viropro plans for restructuring following facility seizure

Wednesday, February 4, 2015 01:23 PM

Viropro, an integrated developer and manufacturer of biopharmaceutical products based in San Jose, Calif., has announced that its board of directors completed its strategic review and has begun the implementation of a restructuring designed to restore the company to financial health. 

More... »

OptiKira launched by BioMotiv, UCSF, University of Washington

Wednesday, February 4, 2015 01:18 PM

BioMotiv, a drug development accelerator associated with The Harrington Project, the University of California San Francisco (UCSF) and University of Washington, Seattle, have announced the formation of OptiKira, a platform company that will develop small molecule therapeutics that prevent cell death in pathologies caused by misfolded or unfolded proteins.

More... »

Astellas broadens commitment to clinical trial data transparency

Monday, February 2, 2015 01:57 PM

Astellas Pharma, based in Japan, will now make trial data available through, an independent web site that enables researchers to request and access clinical trial data after approval of a research proposal by an independent review panel.

More... »

Biogen Idec begins 2015 with multiple collaborations

Monday, February 2, 2015 01:45 PM

Biogen Idec left 2014 with cash, cash equivalents and marketable securities totaling approximately $3.3 billion and has begun 2015 with multiple collaborations. The company expects to continue to bolster its R&D capabilities in the coming months.

More... »

Valeant to acquire assets from bankrupt Dendreon

Monday, February 2, 2015 01:41 PM

Valeant Pharmaceuticals International, based in Canada, has entered into a "stalking horse" asset purchase agreement to acquire certain assets of Seattle, Wash.-based biotechnology company Dendreon for $296 million in cash.

More... »

Endo Pharmaceuticals completes acquisition of Auxilium Pharmaceuticals

Monday, February 2, 2015 01:38 PM

Endo International has completed the acquisition of Auxilium Pharmaceuticals in a transaction valued at $2.6 billion. The closing of the transaction, which was announced Oct. 9, 2014, follows approval by Auxilium's shareholders on Jan. 27 and the receipt of all required regulatory approvals.

More... »


March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs